Barclays’s Oruka Therapeutics ORKA Stock Holding History

Barclays’s Portfolio ORKA Stock Details ORKA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$14.2M	Buy	170,500 +95,738	+128%	+$9.02M	﹤0.01%	1437
2026 Q2	$7.12M	Sell	74,762 -10,975	-13%	-$731K	﹤0.01%	1657
2026 Q1	$4.21M	Sell	85,737 -87,592	-51%	-$3.04M	﹤0.01%	1926
2025 Q4	$5.25M	Buy	173,329 +77,999	+82%	+$2.17M	﹤0.01%	2179
2025 Q3	$1.83M	Buy	95,330 +4,166	+5%	+$61.8K	﹤0.01%	2949
2025 Q2	$1.02M	Buy	91,164 +15,831	+21%	+$165K	﹤0.01%	3326
2025 Q1	$773K	Buy	75,333 +750	+1%	+$9.35K	﹤0.01%	3260
2024 Q4	$1.45M	Buy	+74,583	New	+$1.82M	﹤0.01%	3129
2023 Q2	–	Sell	-4	Closed	-$98	–	5160
2023 Q1	$98	Buy	+4	New	+$105	﹤0.01%	4997
2018 Q2	–	Hold	0	–	–	–	7347
2018 Q1	–	Hold	0	–	–	–	7387

Other funds holding ORKA

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 24.61% 1-Year Est. Return

Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

SEB Asset Management Stockholm $27B AUM

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Synergy Asset Management Vancouver, Washington $1.09B AUM 33.1% 1-Year Est. Return

Barclays's ORKA Position: Q3 2026 in Review

Barclays increased its Oruka Therapeutics (ORKA) stake by 128% in Q3 2026, buying an estimated $9.02M and bringing the position to 170,500 shares worth $14.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1437.

Barclays first reported a position in ORKA in Q1 2023 and has held it in 9 quarters since. 78 funds tracked by Wall St. Rank hold ORKA as of Q3 2026.

Barclays held 170,500 shares of Oruka Therapeutics worth $14.2M as of Q3 2026.
Barclays bought 95,738 Oruka Therapeutics shares in Q3 2026, an estimated $9.02M.
Oruka Therapeutics made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #1437 holding.
Barclays first reported a position in Oruka Therapeutics in Q1 2023 and has held it in 9 quarters since.
78 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.